Latest Guidance UpdatesApril 2022: updates to Table 1 on the clinical treatment of psoriasis on the trunk and limbs, scalp, and nails. |
Overview
An easy-to-follow summary of the Primary Care Dermatology Society's treatment pathway for the assessment and management of psoriasis based on areas affected.
What is Psoriasis?
- Psoriasis is a chronic, relapsing, inflammatory condition affecting the skin, scalp, nails, flexures, and joints, with cardiovascular and psychological comorbidities
- It is not contagious and there is often a family history
- Psoriasis typically manifests with sharply demarcated dull red plaques with silvery scales, which shed easily
- It can be well controlled and treatment aims are to minimise skin manifestations and comorbidities and improve quality of life.
Triggers and Exacerbating Factors
- Stress
- Smoking, alcohol, and obesity
- Skin injury/surgery
- Infections—Streptococci, HIV
- Drugs (oral), such as lithium, beta-blockers, terbinafine, and antimalarials such as hydroxychloroquine.
Assessment
- A holistic approach is essential
- Examine the skin:
- body
- special sites—scalp and nail involvement and specifically ask about genital areas
- joints—be alert to signs of inflammatory arthritis including tendonitis and heel pain
- cardio-metabolic risk (e.g. modified QRISK)
- cardiovascular risk assessment, smoking, and alcohol consumption
- explore wellbeing (e.g. 'how are you coping?’).
Management
- Explore expectations and discuss treatment options initially using topical therapies
- Emphasise benefits of lifestyle changes and provide support
- Arrange follow up and consider primary healthcare team’s role in review of psoriasis and management of comorbidities
- Dermatology Life Quality Index (DLQI)
- Psoriasis Epidemiology Screening Tool (PEST).
Lifestyle Directed Advice
- Lifestyle change, reducing obesity, smoking, and alcohol, and managing psychological comorbidities have been shown to improve psoriasis severity. Provide advice on managing stress, smoking and alcohol, diet, and physical exercise. Utilise local resources where available
- Natural sunlight can improve psoriasis in some. However, sun beds and exposing oneself to excessive periods in the sun is not recommended, especially in patients with very fair complexions, as this risks skin cancer and burning.
Skin-Directed Treatment
- We strongly advocate the use of emollients both as soap substitutes and leave-on preparations for all patients, alongside active topical therapies. Emollients soften scale, relieve itch, and reduce discomfort and should be prescribed in large quantities (500 g/week for an adult, 250–500 g/week for a child). When choosing an emollient, patient preference is crucial for adherence
- Active topical treatments should be used daily during a flare. During remissions, improvement should be sustained by using less frequent active topical treatment (apply twice weekly, on Monday and Friday, or Saturday and Sunday).
Table 1: Psoriasis—Clinical Features and Treatment
Clinical Features | Treatment |
---|---|
Trunk and Limbs | |
|
|
Scalp Psoriasis | |
|
|
Flexures and Genitalia | |
|
|
Face | |
|
|
Guttate Psoriasis | |
|
|
Palmoplantar Pustular | |
|
|
Nails | |
|
|
Psoriatic Arthritis | |
|
|
Calcipitriol/betamethasone combination products are available as ointments and gel (Dovobet® ointment and gel), foam (Enstilar® foam), and cream (Wynzora® cream). Choose the formulation that the patient may comply with, e.g. foam, gel, or cream for scalp; foam or cream for nails; and any formulation for trunk and limb psoriasis. Enstilar foam is licensed for body active (acute) treatment but also maintenance therapy. Total usage of any formulation should not exceed more than 30% body surface area or more than 15 g a day. | |
PUVA=psoralen and ultraviolet A |
Referral
Immediate Referral if:
- Erythroderma (more than 90% skin coverage)
- Severe worsening psoriasis and systemically unwell patient
- Generalised pustular psoriasis.
Routine/Urgent Referral if:
- Poor response to treatment
- Severe psoriasis or widespread psoriasis (more than 10% body surface area)
- Psychological distress.
Other Information
- Assessing psychological distress with DLQI score
- Assessing psoriatic arthritis with PEST score
- Reduce costs of multiple prescriptions by advising a pre-payment certificate
- Further information for patients can be found at www.pcds.org.uk and www.psoriasis-association.org.uk.